Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: Similar results in 2 months

Clinical Infectious Diseases

Volumn 38, Issue 6, 2004, Pages 895-902

  Mwamburi, D Mkaya ^a   Gerrior, Jül ^b   Wilson, Ira B ^a   Chang, Hong ^a   Scully, Ed ^d   Saboori, Shiva ^d   Miller, Laurel ^e   Forfia, Janet ^e   Albrecht, Mary ^c   Wanke, Christine A ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Greater Lawrence Family Health Center   (United States)

^e Gtr New Bedford Comm Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; MEGESTROL ACETATE; OXANDROLONE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ANDROGEN;

ACNE; ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; EDEMA; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; LIBIDO DISORDER; LIVER TOXICITY; MALE; MENSTRUATION DISORDER; NAUSEA; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; PATHOPHYSIOLOGY;

ADULT; ANDROGENS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MEGESTROL ACETATE; OXANDROLONE; WEIGHT GAIN; WEIGHT LOSS;

EID: 12144289583     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381977     Document Type: Article

References (28)

1. Kotler DP, Tierney AR, Wang J, Pierson RN Jr. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989; 50:444-7.
2. Nahlen BL, Chu SY, Nwanyanwu OC, Berkelman RL, Martinez SA, Rullan JV. HIV wasting syndrome in the United States. AIDS 1993; 7:183-8.
3. Wanke CA, Silva M, Knox TA, Forrester J, Speigelman D, Gorbach SL. Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 2000; 31:803-5.
4. Tang AM, Forrester J, Spiegelman D, Knox TA, Tchetgen E, Gorbach SL. Weight loss and survival in HIV-positive patients in the era of highly active antiretroviral therapy. J Aquir Immune Defic Syndr 2002; 31:230-6.
5. Hellerstein MK, Kahn J, Mudie H, Viteri F. Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 1990; 17(Suppl 9):17-33.
6. Kotler DP. Wasting syndrome: nutritional support in HIV infection. AIDS Res Hum Retroviruses 1994; 10:931-4.
7. Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS. AIDS 1995; 9:1107-8.
8. Balog DL, Epstein ME, Amodio-Groton MI. HIV wasting syndrome: treatment update. Ann Pharmacother 1998; 32:446-58.
9. Chlebowski RT, Grosvenor M, Lillington L, Sayre J, Beall G. Dietary intake and counseling, weight maintenance, and the course of HIV infection. J Am Diet Assoc 1995; 95:428-32; quiz 433-5.
10. Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000; 75:386-94.
11. Von Roenn JH, Murphy RL, Wegener N. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 1990; 17(6 Suppl 9):13-6.
12. Clarick RH, Hanekom WA, Yogev R, Chadwick EG. Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus. Pediatrics 1997; 99:354-7.
13. Batterham MJ, Garsia R. A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss. Int J Androl 2001; 24:232-40.
14. Maguen S, Wagner GJ, Rabkin JG. Long-term testosterone therapy in HIV-positive men: side-effects and maintenance of clinical benefit. AIDS 1998; 12:327-8.
15. Farrar DJ. Megestrol acetate: promises and pitfalls. AIDS Patient Care STDS 1999; 13:149-52.
16. Summerbell CD, Youle M, McDonald V, Catalan J, Gazzard BG. Megestrol acetate vs cyproheptadine in the treatment of weight loss associated with HIV infection. Int J STD AIDS 1992; 3:278-80.
17. Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M. Studies of high-dose megestrol acetate: potential applications in cachexia. Sem Oncol 1988; 15(Suppl 1):68-75.
18. Berger JR, Pall L, Hall CD, Simpson DM, Berry PS, Dudley R. Oxandrolone in AIDS-wasting myopathy. AIDS 1996; 10:1657-62.
19. Hellerstein M, Strawford A. Resistance exercise and oxandrolone for men with HIV-related weight loss. JAMA 2000; 284:176-7.
20. Muurahainen N, Mulligan K. Clinical trials update in human immunodeficiency virus wasting. Semin Oncol 1998; 25(Suppl6):104-11.
21. Taiwo BO. HIV-associated wasting: brief review and discussion of the impact of oxandrolone. AIDS Patient Care STDS 2000; 14:421-5.
22. Von Roenn JH, Murphy RL, Weber KM, Williams LM, Weitzman SA. Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 1988; 109:840-1.
23. Durnin JV, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 1974; 32:77-97.
24. Lukaski H. Use of bioelectric impedance analysis to assess human body composition: a review. In: Livingstone, GE, ed. Nutritional assessment of an individual. Trumbull, CT: Food and Nutrition Press, 1989:189-204.
25. Ware J Jr, Kosinski M, Keller SD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996; 34:220-33.
26. Centers for Disease Control and Prevention. Revision of the CDC surveillance case definition for acquired immunodieficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. MMWR Morb Mortal Wkly Rep 1987; 36(Suppl 1):3S-15S.
27. Fischer A, Abbaitola M. The effects of oxandrolone on body weight and composition in patients with HIV-related weight loss [abstract 42351], Geneva, Switzerland: Program and abstracts of the 12th World AIDS Conference, 1998.
28. Perez De Oteyza C, Garcia Cortes A, Menendez Martinez MA, Torres Leon JM, Perez Aznar C, Carnicero Bujarrabal M. Megestrol in the treatment of AIDS associated cachexia: evaluation by bioelectric impedance analysis of body composition. An Med Interna 1998; 15:255-8.